We use a unique science-driven approach to engineer endolysins and bacteriophages into targeted antibacterial treatments, leveraging the high potential of both technologies for our proprietary products.

Engineering Endolysins

We create endolysins optimized for specific and effective antibacterial treatments using advanced molecular engineering techniques. Our molecules selectively target harmful bacteria – including antibiotic resistant strains – which cause and exacerbate acute and chronic illnesses. The natural bacteria of the microbiome, beneficial for our health, remain unaffected. Due to the unique mode of action of endolysins, the emergence of resistance is extremely unlikely.

Engineering Antimicrobial Vectors

Our engineered antimicrobial vector technology is leveraging the genetic scaffold of bacteriophages to engineer novel and patentable precision antimicrobials as a new class of biologics for the treatment of antimicrobial-resistant (AMR) bacterial infections.

Our state-of-the art Drug Discovery unit for endolysins and antimicrobial vectors is based in Zurich, Switzerland.

Application of engineered endolysins

Micreos is bringing engineered endolysin-based treatments to patients suffering from diseases that are caused or aggravated by pathogenic bacteria. This approach is currently being applied to four therapeutic areas:

CTCL header

Beyond Resistance
in Cutaneous T-cell Lymphoma (CTCL)

Colonization of the skin with Staphylococcus aureus (S. aureus) has a dual effect on patients with cutaneous T-cell lymphoma (CTCL) contributing to skin symptoms and also proliferation of malignant T-cells and disease progression.

CTCL has a profound impact on patients’ quality of life due to its chronic nature and the fact that a considerable proportion of patients have no response or no sustainable response to current treatments.

Our clinical development of XZ.700 aims to give CTCL patients a treatment option with a completely new mode of action compared to existing therapies. XZ.700:

  • Specifically targets and kills S. aureus on the skin without causing resistance
  • Improves outcomes for patients by treating skin symptoms and reducing tumor progression
  • Allows for long-term treatment of skin lesions with the potential to reduce infection complications
  • Is well tolerated

We anticipate its use as a topical treatment of the inflammatory skin symptoms associated with CTCL and for the reduction of disease activity and tumor load in adult patients with CTCL.

Prevalence of this incurable, orphan malignancy in the US in 2022 is estimated to be 64,690.

CTCL body

We welcome collaboration with partners who share our ambition to address the impact of bacterial infection on chronic and acute illness. Please contact Natalie Samuel:

contact@micreos.com
AD header

Beyond Resistance
in Atopic Dermatitis (AD)

Colonization of the skin with Staphylococcus aureus (S. aureus) in people with Atopic Dermatitis (AD) plays a significant role in the pathophysiology and severity of the condition. S. aureus produces virulence factors which contribute towards inflammation, skin barrier dysfunction, pruritus, and increased risk of infection.

Due to the chronic nature of the disease AD has a significant long-term impact on quality of life of patients in health-related aspects such as physical, psychosocial, and mental functioning. This means it is imperative to have treatments which are well tolerated and can be used long-term.

MEndoA is first-in-class with a completely new mode of action to existing therapies. Through our clinical development of MEndoA, we want to give all AD patients a treatment option which:

  • Kills S. aureus, including resistant strains, while leaving the rest of the microbiome intact
  • Can be used long-term to help control their disease without inducing resistance, unlike antibiotics
  • Is well tolerated

MEndoA has the potential to be used across the treatment paradigm – for treatment of flares and as maintenance to prevent flares – in people with mild, moderate or severe AD.

In a meta-analysis, the pooled prevalence of S. aureus colonization among patients was 70% for lesional skin.

We welcome collaboration with partners who share our ambition to address the impact of bacterial infection on chronic and acute illness. Please contact Natalie Samuel:

contact@micreos.com

Beyond Resistance
in Diabetic Foot Ulcer (DFU)

Staphylococcus aureus (S. aureus) is one of the most prominent pathogens in infected Diabetic Foot Ulcers (DFU). Patients with infected DFUs often require intensive treatments which may include multiple courses of antibiotics. Given the size of the patient population and frequency of infection it is contributing to the growing problem of antibiotic resistance.

Approximately 20% of moderate or severe diabetic foot infections lead to some level of amputation.

MEndoD has the potential to be an effective antimicrobial to control S. aureus in people with DFU, which:

  • Has a unique specificity for S. aureus, including MRSA, while preserving healthy bacteria
  • Does not induce resistance
  • May be given with other therapeutic products
  • Is well tolerated

Prevalence rates of S. aureus are as high as 80% in severe infected ulcers.

We welcome collaboration with partners who share our ambition to address the impact of bacterial infection on chronic and acute illness. Please contact Natalie Samuel:

contact@micreos.com

Beyond Resistance
in Bacterial Bloodstream Infection

Staphylococcus aureus (S. aureus) is the most common bacterial species in Gram-positive associated bacterial bloodstream infection (BBI), with Staphylococcus epidermidis (S. epidermidis) as another leading cause. BBI is a medical emergency, and even more so when antibiotic resistant bacteria are involved, hence there is a pressing need for new treatment options. The proposed indication for MEndoB is for the treatment of staphylococcal bloodstream infections in neonates, children, and adults.

MEndoB is an endolysin specifically designed for the treatment of Staphylococcus spp. and S. epidermidis bloodstream infections. MEndoB is being investigated:

  • As a first-in class treatment to specifically target and treat S. aureus and S. epidermidis bloodstream infections without inducing resistance
  • For patients with resistant forms of S. aureus – most importantly MRSA
  • For infections with biofilm formation, causing traditional antibiotics to be ineffective

 

The 30-day mortality rate for S. aureus bacteraemia is 10-40% depending on the country.

We welcome collaboration with partners who share our ambition to address the impact of bacterial infection on chronic and acute illness. Please contact Natalie Samuel:

contact@micreos.com